We want to resolve one of the problems that is often raised by pharmaceutical companies, particularly during hearings, when we are addressing a contravention. When companies improve their drugs so that they have a better effect, companies should be able to get a better price. Yet, the current guidelines do not allow us to accede to their request.
On February 12th, 2009. See this statement in context.